Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)

Trial Details

NCT ID

NCT05976997

Phase

PHASE2

Sponsor

Liling Zhang

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

• Duvelisib, Chidamide

Locations (sample)

• Wuhan, Hubei, China|30.58333,114.26667

Key Eligibility Criteria

• Age: 18-70 Years (Contains boundary values 18 and 70);
• The newly diagnosed PTCL confirmed by histopathology is one of the following subtypes;
• a) Angioimmunoblastic T-cell lymphoma (AITL); b) Follicular T helper cell lymphoma (T-FHCL); Including but not limited to the above two subtypes;
• At least one measurable or evaluable tumor lesion according to the Lugano-2014 standard;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.